Pretreatment Factors Associated With Pain Improvement After Cernitin Pollen Extract Therapy in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Post Hoc Analysis.

Authors

Yoshihisa Matsukawa, Yushi Naito, Satoshi Inoue, Tomokazu Kimura, Momokazu Gotoh, Shusuke Akamatsu

Published in

Lower urinary tract symptoms. Volume 18. Issue 4. Pages e70078.

Abstract

Cernitin pollen extract is used for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), but pretreatment factors associated with pain improvement remain unclear. This study explored baseline factors associated with clinically meaningful pain relief after cernitin therapy in men with CP/CPPS.
This exploratory post hoc analysis was based on a single-center, open-label, randomized prospective trial conducted between July 2017 and December 2018. Men with persistent CP/CPPS despite at least 12 weeks of α1-blocker therapy were randomized to receive add-on cernitin pollen extract or tadalafil for 12 weeks. The present analysis included 42 men assigned to cernitin. Good responders were defined as patients with a ≥ 50% improvement in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) pain subscore. Baseline variables were compared, and exploratory logistic regression analysis with a limited number of covariates was performed.
Among 42 patients, 21 were good responders and 21 were poor responders. The NIH-CPSI pain subscore improved by 67.0% in good responders and by 28.9% in poor responders (p < 0.001). Baseline serum total testosterone was significantly lower in good responders than in poor responders (4.5 ± 2.9 vs. 6.3 ± 2.4 ng/mL; p = 0.006). In exploratory multivariable analysis, lower serum total testosterone remained the only factor associated with clinically meaningful pain improvement (odds ratio 0.53, 95% confidence interval 0.30-0.95; p = 0.033).
Lower pretreatment serum total testosterone was associated with clinically meaningful pain improvement after cernitin therapy. These findings are hypothesis-generating and require validation in larger prospective cohorts.

PMID:
42385186
Bibliographic data and abstract were imported from PubMed on 02 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.